There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of sarcomain a patient in need thereof.

The invention relates to a marker body (10) for marking breast tissue for radiotherapy. The marker body (10) has an at least partly tube-like body (12) which is made from a soft elastic material and carries multiple radio-opaque marker elements (18). The at least partly tube-like body (12) is designed so that it offers hardly any resistance to an external, deforming force, but returns to its original shape in the absence of external forces. The at least partly tube-like body (12) has two free longitudinal ends (14, 16) which can be detachably interconnected or are interconnected, resulting in a tubular ring.

The present disclosure provides a composition, a combination product, a medical device and the like for treating or preventing cancer or a tumor or preventing the recurrence of the cancer or the tumor. The present disclosure provides a composition, a combination product and a medical device for treating or preventing cancer or a tumor or preventing the recurrence of the cancer or the tumor, each of which comprises an immune checkpoint inhibitor and a dendritic cell direct activator or means. In another aspect, the present disclosure provides: a novel cancer treatment method which comprises carrying out a treatment of cancer by employing a combination of a treatment by the administration of an immune checkpoint inhibitor and a treatment for improving the sensitivity to the immune checkpoint inhibitor and, therefore, can be used as an immunotherapy that can be expected to have an excellent therapeutic effect; and a medicine which can be used for the cancer treatment method.

The present disclosure provides a composition, a combination product, a medical device and the like for treating or preventing cancer or a tumor or preventing the recurrence of the cancer or the tumor. The present disclosure provides a composition, a combination product and a medical device for treating or preventing cancer or a tumor or preventing the recurrence of the cancer or the tumor, each of which comprises an immune checkpoint inhibitor and a dendritic cell direct activator or means. In another aspect, the present disclosure provides: a novel cancer treatment method which comprises carrying out a treatment of cancer by employing a combination of a treatment by the administration of an immune checkpoint inhibitor and a treatment for improving the sensitivity to the immune checkpoint inhibitor and, therefore, can be used as an immunotherapy that can be expected to have an excellent therapeutic effect; and a medicine which can be used for the cancer treatment method.

The present disclosure relates to a method of treating a glioblastoma by conjointly administering to a subject a BCL-xL inhibitor and a second therapy such as an alkylating agent, irradiation, or an MCL-1 inhibitor.

A control method for positioning is provided, which is applicable to a radiotherapy system. The method includes: acquiring a plurality of first body surface coordinates of a target site in a three-dimensional body surface image of a treatment object on a treatment couch; acquiring a plurality of second body surface coordinates under an isocentric coordinate system by transforming the first body surface coordinates using a target transformation matrix corresponding to the first placement position; determining, based on the plurality of second body surface coordinates and a contour image of the target site in the treatment plan, a placement offset of the target site, so as to control the treatment couch to move until the placement offset of the target site upon the movement meets a target offset requirement.

The present invention provides an immunomodulator for use in the treatment and/or control of a neoplastic disease in a patient intended to undergo immunogenic cell death therapy simultaneously, separately or sequentially with administration of the immunomodulator. The therapy can be selected from microwave irradiation, targeted radiotherapy, embolisation, cryotherapy, ultrasound, high intensity focused ultrasound, cyberknife, hyperthermia, radiofrequency ablation, cryoablation, electrotome heating, hot water injection, alcohol injection, embolization, radiation exposure, photodynamic therapy, laser beam irradiation, and combinations thereof.

The disclosure provides a phantom and method for quality assurance of a hadron therapy apparatus used in the intensity modulated particle therapy mode. The phantom comprises a frame structure comprising a base plate, one or more energy wedges, an energy wedge first face inclined with respect to said base plate and an energy wedge second face perpendicular to said base plate, said one or more energy wedges being mounted on said base plate, a 2D detector; said one or more wedges, and 2D detector being in known fixed positions in relation to said frame structure. Said phantom comprises in addition a Spread-Out Bragg Peak wedge, said SOBP wedge having an SOBP wedge first face inclined with respect to said base plate, and a SOBP wedge second face, perpendicular to said base plate, said SOBP wedge being made of a material having a relative density higher than 1.3 preferably 1.5, more preferably 1.7, the distance between the SOBP wedge first face and SOBP second face varying between the penetration depth of a beam having an energy between the high and low limit energy of the beam of said hadron therapy apparatus. The disclosure also provides a method for determining the compliance of the planned SOBP with the actual SOBP.

Techniques for generating radiotherapy treatment plans and establishing machine learning models for the generation and optimization of radiotherapy dose data are disclosed. An example method for generating a radiotherapy dose distribution using a generative model, trained in a generative adversarial network, includes: receiving anatomical data of a human subject that indicates a mapping of an anatomical area for radiotherapy treatment; generating radiotherapy dose data corresponding to the mapping with use of the trained generative model, as the generative model processes the anatomical data as an input and provides the dose data as output; and identifying the radiotherapy dose distribution for the radiotherapy treatment of the human subject based on the dose data. Another example method for training of the generative model includes establishing values of the generative model and a discriminative model of the generative adversarial network using adversarial training, including in a conditional generative adversarial network arrangement.

It is provided a method for optimizing a treatment plan for use in radiation therapy. The method is performed in a treatment planning system and comprises the steps of: obtaining a first quality function of the treatment plan, the first quality function yielding an output value based on an input treatment plan; obtaining a first pair of input values and a slope indicator, the input values associating a value of the first quality function to a value of a score; constructing a score function that maps values of the first quality function to values of the score by fitting a curve to the first pair of input values and the slope indicator; and optimizing the treatment plan with respect to the score function, by varying the treatment plan such that the value of the score function is either improved or constrained to a feasible range of score values.